JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4070 Elvitegravir (GS-9137)

Target: HIV Integrases

Summary: HIV-1 integrase inhibitor,potent

insoluble in H2O; insoluble in EtOH; ≥20.35 mg/mL
A4073 Raltegravir (MK-0518)
1 Citation

Target: integrase

Summary: HIV-1 integrase inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.95 mg/mL
A8203 Ritonavir

Summary: HIV protease inhibitor

≥26 mg/mL
A4186 Bromosporine
1 Citation

Target: Bromodomains

Summary: Bromodomain inhibitor,non-selective

≥40.4 mg/mL
A3253 BMS-626529
2 Citation

Target: HIV-1 gp120

Summary: HIV-1 attachment inhibitor

insoluble in H2O; insoluble in EtOH; ≥1.48 mg/mL
A3384 Elacridar

Target: P-glycoprotein (P-gp)

Summary: BCRP inhibitor

≥56.4 mg/mL
B5916 Chidamide
1 Citation

Target: HDAC

Summary: Novel HDAC inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.55 mg/mL
B3471 Medroxyprogesterone

Target: Progesterone Receptors

Summary: potent progesterone receptor agonist

≥34.4 mg/mL
B3705 YYA-021

Target: gp120-CD4 interaction

Summary: Competitive gp120-CD4 interaction inhibitor
B2224 Etravirine (TMC125)

Target: Reverse Transcriptases

Summary: Reverse transcriptase inhibitor

insoluble in EtOH; insoluble in H2O; ≥19.35 mg/mL